MVP-06-01 / Oncovita - LARVOL DELTA

In situ cancer immunotherapy with modified MVdeltaC measles virus induces potent RIG-I–dependent tumor clearance and immune memory (EACR 2026) - "These findings establish MVdeltaC as a clinically ready, broad-spectrum immunotherapeutic that links RIG-I activation by defective viral genome generation to elicit potent and durable antitumor immunity."

Bladder Cancer • Breast Cancer • Cervical Cancer • Infectious Disease • Measles • Melanoma • Mesothelioma • Neuroblastoma • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • CD4 • CD46 • CD8

MVdeltaC has been granted the Orphan Drug Status by the…EMA for mesothelioma use (GlobeNewswire)

Orphan drug • Mesothelioma

Oncovita presents promising preclinical data on MVdeltaC, a novel onco-immunotherapy at EACR, 8-11 June 2026, in Budapest (GlobeNewswire) - "This presentation will include results obtained from in vitro and in vivo models of solid tumor, including PDX models and syngeneic models in immunocompetent mice, such as mesothelioma, bladder, TNBC and neuroblastoma....Detailed investigations of the biological MOA allow to conclude to the activation of RIG-I receptor by the defective viral RNA molecules massively generated by the modified measles virus which results in strong innate and adaptive immune activation against the tumors. Finally, an investigation using IA, in collaboration with Infinitusbio.AI, concludes that MVdeltaC has more impact than MV on 70% of the 104 cancer biomarkers."

Preclinical • Bladder Cancer • Mesothelioma • Neuroblastoma • Triple Negative Breast Cancer

Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma (The Manila Times) - "Oncovita...announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead investigational therapy, MVdeltaC, for the treatment of pleural mesothelioma-a rare and aggressive cancer with high unmet medical need and limited therapeutic options....'This regulatory support strengthens our strategy to advance innovative immunotherapies as we prepare to enter clinical development with MVdeltaC by 2026.'"

New trial • Orphan drug • Pleural Mesothelioma